Polso received initial indications for monitoring blood oxygen saturation (SpO2), pulse rate and respiration rate.
Yokneam, Israel-based ChroniSense designed Polso to combine a monitor, mobile app and cloud-based platform. The medical-grade, wrist-worn vital sign monitor pairs with a mobile app for patients. The cloud-based platform for clinicians monitors in-life patient data.
“FDA clearance is a significant milestone towards the commercialization of Polso Connect and towards creating a new model in chronic care management,” said ChroniSense Medical CEO Bridget Ross. “With six out of 10 adults in the U.S. living with a chronic condition and over $1.1 trillion in direct healthcare costs annually1, there is a serious need for an easy-to-use, medical grade, remo…